Jump to: navigation, search
Ethchlor Wiki Str.png
Systematic (IUPAC) name
CAS number 113-18-8
ATC code N05CM08
PubChem 3281
DrugBank APRD00958
Chemical data
Formula C7H9ClO 
Mol. mass 144.598 g/mol
Pharmacokinetic data
Bioavailability  ?
Protein binding 35-50%
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.


Legal status

Schedule IV[1]

Routes Oral

WikiDoc Resources for Ethchlorvynol


Most recent articles on Ethchlorvynol

Most cited articles on Ethchlorvynol

Review articles on Ethchlorvynol

Articles on Ethchlorvynol in N Eng J Med, Lancet, BMJ


Powerpoint slides on Ethchlorvynol

Images of Ethchlorvynol

Photos of Ethchlorvynol

Podcasts & MP3s on Ethchlorvynol

Videos on Ethchlorvynol

Evidence Based Medicine

Cochrane Collaboration on Ethchlorvynol

Bandolier on Ethchlorvynol

TRIP on Ethchlorvynol

Clinical Trials

Ongoing Trials on Ethchlorvynol at Clinical

Trial results on Ethchlorvynol

Clinical Trials on Ethchlorvynol at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Ethchlorvynol

NICE Guidance on Ethchlorvynol


FDA on Ethchlorvynol

CDC on Ethchlorvynol


Books on Ethchlorvynol


Ethchlorvynol in the news

Be alerted to news on Ethchlorvynol

News trends on Ethchlorvynol


Blogs on Ethchlorvynol


Definitions of Ethchlorvynol

Patient Resources / Community

Patient resources on Ethchlorvynol

Discussion groups on Ethchlorvynol

Patient Handouts on Ethchlorvynol

Directions to Hospitals Treating Ethchlorvynol

Risk calculators and risk factors for Ethchlorvynol

Healthcare Provider Resources

Symptoms of Ethchlorvynol

Causes & Risk Factors for Ethchlorvynol

Diagnostic studies for Ethchlorvynol

Treatment of Ethchlorvynol

Continuing Medical Education (CME)

CME Programs on Ethchlorvynol


Ethchlorvynol en Espanol

Ethchlorvynol en Francais


Ethchlorvynol in the Marketplace

Patents on Ethchlorvynol

Experimental / Informatics

List of terms related to Ethchlorvynol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Ethchlorvynol is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists.

Along with expected sedative effects of relaxation and drowsiness ethchlorvynol can cause skin rashes, faintness, restlessness and euphoria. Early adjustment side effects can include nausea and vomiting, numbness, blurred vision, stomach pains and temporary dizziness. An overdose is marked by confusion, fever, peripheral numbness and weakness, reduced coordination and muscle control, slurred speech, reduced heartbeat.

It is addictive and after prolonged use can cause withdrawal symptoms including convulsions, hallucinations, and memory loss. Due to these problems, it is unusual for ethchlorvynol to be prescribed for periods exceeding seven days.

Ethchlorvynol is a member of the class of sedative-hypnotic tertiary carbinols, which inludes methylparafynol. It is not a barbituric acid derivative. The systematic name of ethchlorvynol is usually given as ethyl 2-chlorovinyl ethynyl carbinol or 1-chloro-3-ethyl-1-penten-4-yl-3-ol. Its empirical formula is C7H9ClO. In the United States Abbott Laboratories used to sell it under the tradename Placidyl. During their heyday, they were known on the street as "jelly-bellies". Since Abbott and Banner Pharmacaps, which manufactured the generic version, discontinued production in 1999, ethchlorvynol is no longer available in the United States.

Ethchlorvynol as it relates to William Rehnquist

Placidyl is the drug prescribed for William Rehnquist as treatment of insomnia after back surgery in 1971, according to FBI files obtained after Rehnquist's death. Before he was hospitalized in 1981, court employees noticed that Rehnquist's speech was slurred and that he seemed to be having mental lapses. The hospital doctors took him off the medication, causing withdrawal symptoms, which included hallucinations.[2]

One of the physicians who treated Rehnquist for Placidyl withdrawal, according to the FBI files, described auditory hallucinations in the form of voices discussing him outside his hospital room. At one point the Justice tried to flee the hospital in his pajamas, specifically because of the mistaken belief that the CIA was plotting against him.[3]

Ethchlor Box.png


  1. Green List: Annex to the annual statistical report on psychotropic substances (form P) 23rd edition. August 2003. International Narcotics Board, Vienna International Centre. Accessed 1 September 2005 (UTC)
  2. Legal Times. Accessed 4 January 2007 (UTC)
  3. Sherman, Mark, Pete Yost. "FBI Files: Rehnquist Had Hallucinations",, Jan 04 2007. Retrieved on 2007-01-05.